Company Filing History:
2 out of 1,829 
2 out of 32 
Years Active: 2006-2008
Title: Scott Greenfeder: Innovator in Monoclonal Antibody Technology
Introduction
Scott Greenfeder is a notable inventor based in Metuchen, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies targeting interleukin-5 (IL-5). With a total of 2 patents, his work has implications for both diagnosis and treatment of various conditions.
Latest Patents
Greenfeder's latest patents focus on methods for using human monoclonal antibodies to interleukin-5. The inventions relate to antibodies and antigen-binding portions that specifically bind to human IL-5. They include human anti-IL-5 antibodies, which can be chimeric, bispecific, derivatized, or single-chain antibodies. The patents also cover isolated heavy and light chain immunoglobulin molecules derived from these antibodies, as well as nucleic acid molecules encoding them. Furthermore, the inventions provide methods for making anti-IL-5 antibodies, pharmaceutical compositions containing these antibodies, and methods for their use in diagnosis and treatment. Additionally, gene therapy methods using nucleic acid molecules encoding the immunoglobulin molecules are also included.
Career Highlights
Throughout his career, Scott Greenfeder has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Schering Corporation and Abgenix, Inc. His experience in these organizations has contributed to his expertise in monoclonal antibody technology.
Collaborations
One of his notable coworkers is Jose Corvalan, with whom he has collaborated on various projects in the field of biotechnology.
Conclusion
Scott Greenfeder's innovative work in the development of human monoclonal antibodies has made a significant impact in the field of biotechnology. His contributions continue to influence advancements in medical treatments and therapies.